Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Gu, Ling ^a   Zhou, Chenyan ^a   Liu, Huajun ^a   Gao, Ju ^a   Li, Qiang ^a   Mu, Dezhi ^a   Ma, Zhigui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS ASSOCIATED PROTEIN; BIM PROTEIN; CASPASE 3; CELL CYCLE REGULATORY PROTEIN; CELL PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BAX; PROTEIN MCL 1; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL SEPARATION; DRUG EFFECT; FLOW CYTOMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIROLIMUS;

EID: 78349294588     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-150     Document Type: Article

References (29)

1. Mechanism of glucocorticoid-mediated apoptosis in hematological malignancies. S Greenstein K Ghias NL Krett ST Rosen, Clin Cancer Res 2002 8 1681 1694 12060604
2. Evolution of BFM trials for childhood ALL. M Schrappe, Ann Hematol 2004 83 suppl 1 121 S123 15124702
3. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. S Marino F Verzegnassi P Tamaro G Stocco F Bartoli G Decorti M Rabusin, Pediatr Blood Cancer 2009 53 984 991 10.1002/pbc.22163 19621425
4. Glucocorticoid resistance in childhood leukemia. GJ Kaspers R Pieters E Klumper FC De Waal AJ Veerman, Leuk Lymphoma 1994 13 187 201 10.3109/10428199409056282 8049644
5. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. M van Grotel JP Meijerink ER van Wering AW Langerak HB Beverloo JG Buijs-Gladdines NB Burger M Passier EM van Lieshout WA Kamps AJ Veerman MM van Noesel R Pieters, Leukemia 2008 22 124 131 10.1038/sj.leu.2404957 17928886
6. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). J Soulier E Clappier JM Cayuela A Regnault M García-Peydrá H Dombret A Baruchel ML Toribio F Sigaux, Blood 2005 106 274 286 10.1182/blood-2004-10-3900 15774621
7. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. LJ Lewis-Tuffin JA Cidlowski, Ann N Y Acad Sci 2006 1069 1 9 10.1196/annals.1351.001 16855130
8. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. DT Teachey SA Grupp VI Brown, Br J Hematol 2009 145 569 580 10.1111/j.1365-2141.2009.07657.x
9. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. H Yan P Frost Y Shi B Hoang S Sharma M Fisher J Gera A Lichtenstein, Cancer Res 2006 66 2305 2313 10.1158/0008-5472.CAN-05-2447 16489035
10. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. F Jundt N Raetzel C Müller CF Calkhoven K Kley S Mathas A Lietz A Leutz B Dörken, Blood 2005 106 1801 1807 10.1182/blood-2004-11-4513 15886325
11. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. T Strömberg A Dimberg A Hammarberg K Carlson A Osterborg K Nilsson H Jernberg-Wiklund, Blood 2004 103 3138 3147 10.1182/blood-2003-05-1543 15070696
12. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. G Wei D Twomey J Lamb K Schlis J Agarwal RW Stam JT Opferman SE Sallan ML den Boer R Pieters TR Golub SA Armstrong, Cancer Cell 2006 10 331 342 10.1016/j.ccr.2006.09.006 17010674
13. 1cell cycle arrest and apoptosis. L Gu J Gao Q Li YP Zhu CS Jia RY Fu Y Chen QK Liao Z Ma, Leukemia 2008 2 2091 2096 10.1038/leu.2008.204
14. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. C Vezina A Kudelski SN Sehgal, J Antibiot 1975 28 721 726 1102508
15. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. JJ Gibbons RT Abraham K YU, Semin Oncol 2009 36 suppl 3 3 S17 10.1053/j.seminoncol.2009.10.011 19963098
16. Targeting the mTOR signaling network for cancer therapy. F Meric-Bernstam AM Gonzalez-Angulo, J Clin Oncol 2009 17 2278 2287 10.1200/JCO.2008.20.0766
17. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. LJ Costa, Cancer Treat Rev 2007 33 78 84 10.1016/j.ctrv.2006.10.004 17161912
18. mTOR-targeted therapy of cancer with Rapamycin derivatives. S Vignot S Faivre D Aguirre E Raymond, Ann Onc 2005 16 525 537 10.1093/annonc/mdi113 (Pubitemid 40613318)
19. Upstream and downstream of mTOR. N Hay N Sonenberg, Genes Dev 2004 18 1926 1945 10.1101/gad.1212704 15314020
20. Defining the Role of mTOR in Cancer. DA Guertin DM Sabatini, Cancer cell 2007 12 9 22 10.1016/j.ccr.2007.05.008 17613433
21. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. JK Altman LC Platanias, Current Opin Hematol 2008 15 88 94 10.1097/MOH.0b013e3282f3deaa (Pubitemid 351323147)
22. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. MA Shah GK Schwartz, Clin Cancer Reds 2001 7 2168 2181 11489790
23. Preclinical and clinical development of the cyclindependent kinase inhibitor flavopiridol. GI Shapiro, Clin Cancer Res 2004 10 12pt2 4270s 4275s 10.1158/1078-0432.CCR-040020 15217973
24. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. WJ Tissing JP Meijerink B Brinkhof MJ Broekhuis RX Menezes ML den Boer R Pieters, Blood 2006 108 1045 1049 10.1182/blood-2006-01-0261 16574952
25. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. A Möricke M Zimmermann A Reiter G Henze A Schrauder H Gadner WD Ludwig J Ritter J Harbott G Mann T Klingebiel F Zintl C Niemeyer B Kremens F Niggli D Niethammer K Welte M Stanulla E Odenwald H Riehm M Schrappe, Leukemia 2010 24 265 284 10.1038/leu.2009.257 20010625
26. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic large cell lymphoma kinase-positive anaplatic large cell lymphoma. F Vega LJ Medeiros V Leventaki C Atwell JH Cho-Vega L Tian FX Claret GZ Rassidakis, Cancer Res 2006 66 6589 6597 10.1158/0008-5472.CAN-05-3018 16818631
27. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. E Peponi E Drakos G Reyes V Leventaki GZ Rassidakis LJ Medeiros, Am J Pathol 2006 169 2171 2180 10.2353/ajpath.2006.051078 17148679
28. Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells. S Riml S Schmidt MJ Ausserlechner S Geley R Kofler, Cell Death Differ 2004 11 Suppl1 65 S72 10.1038/sj.cdd.4401413 15017388
29. On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis. WY Almawi OK Melemedjian MM Jaoude, J Leukoc Biol 2004 76 7 14 10.1189/jlb.0903450 15075361